Join­ing hunt for hep B cure, Brii Bio inks maid­en deals fea­tur­ing VBI, Vir, WuXi with a big ap­petite for more

This May, Zhi Hong de­buted the ul­tra-con­nect­ed trans-Pa­cif­ic up­start Brii Bio to bridge a gap in in­no­va­tion be­tween the US and Chi­na. Sev­en months in, he’s us­ing some of those con­nec­tions to in-li­cense two po­ten­tial cures for he­pati­tis B, en­ter an­oth­er dis­cov­ery col­lab­o­ra­tion and build a new glob­al head­quar­ters, kick­start­ing a quest to “cre­ate a new ground for in­fec­tious dis­eases.”

And with plen­ty of his $260 mil­lion launch fund still in the bank, the CEO al­ready has his eyes set on more part­ner­ships — all co­or­di­nat­ed from a new R&D hub be­ing built in Bei­jing, which will even­tu­al­ly be able to house up to 200 em­ploy­ees, as well as small­er out­posts across Shang­hai, San Fran­cis­co and Hong’s home base of Durham, North Car­oli­na.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER